Answers are grounded in this paper and cite their sources.
Barrett’s esophagus (BE) is defined as intestinal metaplasia of the esophageal epithelium and represents the precursor lesion of esophageal adenocarcinoma (EAC), a rapidly increasing cancer in western countries. Metaplastic cells may develop progressive cellular atypia, classified as dysplastic BE, and with advancing grade of dysplasia the risk of developing EAC rises significantly. Therefore, in patients with dysplastic BE endoscopic treatment is indicated. Endoscopic eradication therapy (EET) has revolutionized management of BE associated neoplasia, shifting away from esophagectomy, which is associated with high mortality and morbidity. EET usually comprises endoscopic resection of focal neoplasia, followed by ablation of the residual non-neoplastic BE with the aim to obtain complete reversion to neosquamous epithelium. To date, radiofrequency ablation (RFA) is the first-choice ablation technique due to its proven efficacy in achieving complete eradication of intestinal metaplasia and its safety. However, in a minority of cases, it may be ineffective at BE eradication. Novel ablation modalities, such as cryoballoon ablation or hybrid argon plasma coagulation (Hybrid-APC), are evolving with promising data, but until now may be limited to cases of refractory or persistent disease. The focus of this review is to illustrate the ablation techniques available along with updated literature regarding safety and efficacy of the different modalities.
No takes yet. Share an insight, caveat, or question.
Freund et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: